Company intelligence / Profile preview

Diabnext

Ownership: Private
Development stage: Other

Overview

Diabnext developed and commercialized a digital health platform and mobile app for comprehensive diabetes management. The solution enables automated tracking of blood glucose, insulin dosing, activity levels, and nutrition data. It supports remote monitoring by healthcare providers to improve patient outcomes. Following its acquisition by Glooko in March 2022, the technology continues to be offered under the name "Glooko XT" in France. No clinical trial results are reported as it is a software/device product.

Therapeutic areas: Endocrinology
Modalities: DeviceDigital therapeutic
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Diabnext.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diabnext.

Explore the full profile